150 related articles for article (PubMed ID: 18796517)
1. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study.
Marini H; Bitto A; Altavilla D; Burnett BP; Polito F; Di Stefano V; Minutoli L; Atteritano M; Levy RM; D'Anna R; Frisina N; Mazzaferro S; Cancellieri F; Cannata ML; Corrado F; Frisina A; Adamo V; Lubrano C; Sansotta C; Marini R; Adamo EB; Squadrito F
J Clin Endocrinol Metab; 2008 Dec; 93(12):4787-96. PubMed ID: 18796517
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study.
Marini H; Bitto A; Altavilla D; Burnett BP; Polito F; Di Stefano V; Minutoli L; Atteritano M; Levy RM; Frisina N; Mazzaferro S; Frisina A; D'Anna R; Cancellieri F; Cannata ML; Corrado F; Lubrano C; Marini R; Adamo EB; Squadrito F
Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):332-40. PubMed ID: 19631515
[TBL] [Abstract][Full Text] [Related]
3. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
Zhang G; Qin L; Shi Y
J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
[TBL] [Abstract][Full Text] [Related]
4. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study.
Tai TY; Tsai KS; Tu ST; Wu JS; Chang CI; Chen CL; Shaw NS; Peng HY; Wang SY; Wu CH
Osteoporos Int; 2012 May; 23(5):1571-80. PubMed ID: 21901480
[TBL] [Abstract][Full Text] [Related]
5. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial.
Bitto A; Polito F; Atteritano M; Altavilla D; Mazzaferro S; Marini H; Adamo EB; D'Anna R; Granese R; Corrado F; Russo S; Minutoli L; Squadrito F
J Clin Endocrinol Metab; 2010 Jun; 95(6):3067-72. PubMed ID: 20357174
[TBL] [Abstract][Full Text] [Related]
6. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial.
Marini H; Minutoli L; Polito F; Bitto A; Altavilla D; Atteritano M; Gaudio A; Mazzaferro S; Frisina A; Frisina N; Lubrano C; Bonaiuto M; D'Anna R; Cannata ML; Corrado F; Adamo EB; Wilson S; Squadrito F
Ann Intern Med; 2007 Jun; 146(12):839-47. PubMed ID: 17577003
[TBL] [Abstract][Full Text] [Related]
7. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
8. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study.
Atteritano M; Marini H; Minutoli L; Polito F; Bitto A; Altavilla D; Mazzaferro S; D'Anna R; Cannata ML; Gaudio A; Frisina A; Frisina N; Corrado F; Cancellieri F; Lubrano C; Bonaiuto M; Adamo EB; Squadrito F
J Clin Endocrinol Metab; 2007 Aug; 92(8):3068-75. PubMed ID: 17682090
[TBL] [Abstract][Full Text] [Related]
9. Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial.
Arcoraci V; Atteritano M; Squadrito F; D'Anna R; Marini H; Santoro D; Minutoli L; Messina S; Altavilla D; Bitto A
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28241420
[TBL] [Abstract][Full Text] [Related]
10. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial.
Levis S; Strickman-Stein N; Ganjei-Azar P; Xu P; Doerge DR; Krischer J
Arch Intern Med; 2011 Aug; 171(15):1363-9. PubMed ID: 21824950
[TBL] [Abstract][Full Text] [Related]
11. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
12. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
13. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
16. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
17. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
[TBL] [Abstract][Full Text] [Related]
19. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
20. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
